Trastuzumab emtansine (T-DM1) and ribociclib, an oral inhibitor of cyclin dependent kinase 4 and 6 (CDK 4/6), for patients with metastatic HER2-positive breast cancer: Phase 1b clinical trial.

Authors

Laura Spring

Massachusetts General Hospital Cancer Center, Boston, MA

Laura Spring , Shom Goel , Dejan Juric , Steven J. Isakoff , Stephanie Haddad , Karleen R. Habin , Ian E. Krop , Beverly Moy , Sara M. Tolaney , Aditya Bardia

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

Trastuzumab emtansine (T-DM1) and ribociclib, an oral inhibitor of cyclin dependent kinase 4 and 6 (CDK 4/6), for patients with metastatic HER2-positive breast cancer.

First Author: Laura Spring

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor SHR6390 combined with pyrotinib and letrozole in patients with human epidermal growth factor receptor 2-positive (HER2+), hormone receptor positive (HR+) metastatic breast cancer (MBC): Phase Ib study results.

First Author: Jian Zhang

insert_chart_outlined

Poster

2018 ASCO Annual Meeting

bookmark_border

SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab ﴾HR+ with or without letrozole﴿ in trastuzumab‐pretreated, postmenopausal patients with HER2‐positive metastatic breast cancer.

First Author: Patricia Villagrasa

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

Open-label phase Ib study of entinostat (E), and lapatinib (L) alone, and in combination with trastuzumab (T) in patients (pts) with HER2+ metastatic (mHER2+) breast cancer after progression on trastuzumab.

First Author: Bora Lim